コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fference between the involved and uninvolved free light chain.
2 but also circulate independently in blood as free light chains.
3 e difference between involved and uninvolved free light chains.
4 lonal immunoglobulin or abnormal circulating free light chains.
5 ow molecular weight proteins that include Ig free light chains.
6 of risk models, including flow cytometry and free-light chain analyses, for predicting risk of progre
8 s, immunofixation electrophoresis, and serum free light-chain analysis were performed on all sera col
10 tigated whether a concomitant abnormality in free light chain and immunoglobulin levels could identif
11 individuals had an increase of at least one free light chain and met criteria for light-chain MGUS.
13 eld include the introduction of an assay for free light chains and the use of novel antiplasma cell a
15 y discuss recent advances in AL, such as the free light-chain assay and the role of immunoglobulin li
17 rategies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents
21 g of 82 patients, changes in serum and urine free-light-chains corresponded, but urine became negativ
23 of restarting therapy, median difference of free light chain (dFLC) was 9.9 mg/dL (42% of diagnosis
24 ence between involved minus uninvolved serum free light chains (dFLC) has been established as an inva
25 a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of ba
26 e difference between involved and uninvolved free light chains (dFLCs; > 50 mg/L) in only two thirds
27 easurable disease (measured by assessment of free light chains), Eastern Cooperative Oncology Group (
28 lectrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all sa
29 ignificance (MGUS), as detected by the serum free light chain (FLC) assay increases the risk of progr
32 iple myeloma (SMM), as detected by the serum free light chain (FLC) assay, indicates an increased ris
33 pplicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of
37 ively evaluated serial paraprotein and serum free light chain (FLC) measurements and found that 258 o
39 e median IgM paraprotein was 8 g/L and serum free light chain (FLC) ratio was abnormal in 77 (88%) of
41 cantly associated with progression: abnormal free light-chain (FLC) ratio (<0.26 or >1.65), M-protein
42 d to deposition of monoclonal immunoglobulin free light chains (FLCs) and directly contributes to mor
43 een the extent of reduction of amyloidogenic free light chains (FLCs) and improvement in survival.
47 e), elevated kappa and lambda immunoglobulin free light chains (FLCs) in peripheral blood are associa
48 ssayed monoclonal (M)-proteins, kappa/lambda free light chains (FLCs) in prediagnostic obtained up to
49 igh concentrations of circulating monoclonal free light chains (FLCs) produced by a clonal expansion
50 result of coprecipitation of immunoglobulin free light chains (FLCs) with Tamm-Horsfall glycoprotein
51 cell activation or clonality: immunoglobulin free light chains (FLCs), soluble CD30 (sCD30), and mono
52 trophoresis/immunofixation) and kappa-lambda free light chains (FLCs), we determined longitudinally t
53 ciation between circulating kappa and lambda free light chains (FLCs), which are markers of B-cell dy
54 the production of monoclonal immunoglobulin free light chains (FLCs), which coprecipitate with Tamm-
58 te, and electrolytes measurements as well as free light chain, if available, and urine electrophoresi
61 ed any independent relationship between high free light chain, immunoglobulins and hospital mortality
62 knowledge, abnormalities and associations of free light chain in critically ill adults with sepsis ha
64 corresponded, but urine became negative for free-light-chains in 26 patients, whereas it remained ab
65 Bence Jones protein in urine (immunoglobulin free-light-chains) is characteristic of light-chain mult
66 day 1, high free light chain lambda and high free light chain kappa were seen in 46.5% and 75.3% of t
69 quantify levels of Fab+Fc, the Fab arm, and free light chain (LC) and heavy chain (HC) fragments, we
72 g levels with patterns of organ involvement, free light-chain levels, the levels of cardiac biomarker
74 lasma cell dyscrasia, significant amounts of free light chains, now monoclonal proteins, present to t
75 e compared with that derived from pathologic free light chains or cTnT in patients evaluated before f
76 tolic dysfunction (p < 0.01), the pathologic free light chains (p < 0.05), cardiac troponin-T (cTnT)
77 relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clon
78 n myeloma has been defined by a normal serum free light chain ratio (SFLCR) in addition to the standa
79 need for BM studies; 10% with a normal serum-free light chain ratio had BM plasma cells more than or
80 a requirement for normalization of the serum-free light chain ratio to negative immunofixation studie
81 sis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detect
83 is was done for all samples with an abnormal free light-chain ratio or abnormal protein electrophores
84 Light-chain MGUS was defined as an abnormal free light-chain ratio with no IgH expression, plus incr
85 .3%) of 18,357 people tested had an abnormal free light-chain ratio, of whom 213 had IgH expression t
86 lasma cells, presence of a markedly abnormal free-light-chain ratio (<0.01 or >100), and reduction of
90 eld include the availability of an assay for free light chains, the introduction of new agents which
91 fy gene defects and the measurement of serum free light chains to identify secondary hypogammaglobuli
92 4, and IgM levels, as well as immunoglobulin free light chains, were measured in both patients with a
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。